Roche study shows cancer drug Avastin slows growth

As reported by Reuters, Swiss drug maker Roche have said a new study of cancer drug Avastin showed it significantly extended progression-free survival of people with an aggressive form of brain cancer.

The Phase III AVAglio study met one of its main targets of improving progression-free survival in people with glioblastoma (a very aggressive cancer)

This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy,” Roche said.

The study’s other main endpoint is the expected time of overall survival, the results of this expected in 2013


Are you looking for a new pharmaceutical job in Switzerland or Europe?

Click here to see our latest jobs on Switzerland

Click here to see our latest jobs on Europe


Posted in: Industry News, News
CK Logo in place of featured image